HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Helena Alexandra YuYasushi GotoHidetoshi HayashiEnriqueta Felip FontJames Chih-Hsin YangMartin ReckKiyotaka YohSe-Hoon LeeLuis G Paz-AresBenjamin BessePaolo BironzoDong Wan KimMelissa Lynne JohnsonYi-Long WuThomas JohnSteven KaoToshiyuki KozukiErminia MassarelliJyoti D PatelEgbert F SmitKaren L ReckampQian DongPomy ShresthaPang-Dian FanParul PatelAndrea SporchiaDavid W SternbergDalila SellamiPasi A JannePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970).